Quick Answer
Entera Bio Ltd. reported Stockholders Equity of $13.10 million for the year ending 2025.
- Entera Bio Ltd. showed an increase of +62.1% in Stockholders Equity from 2024 to 2025.
- This data is from Entera Bio Ltd.'s annual report (Form 10-K), filed with the SEC on March 27, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: $15.65 million | Q2 2021: $26.28 million | Q3 2021: $26.28 million | Q1 2022: $19.75 million | Q2 2022: $17.27 million | Q3 2022: $14.31 million | Q1 2023: $10.08 million | Q2 2023: $8.23 million | Q3 2023: $6.24 million | Q1 2024: $8.86 million | Q2 2024: $8.53 million | Q3 2024: $6.45 million | Q1 2025: $19.38 million | Q2 2025: $17.26 million | Q3 2025: $15.23 million.
- Over the full 7 years of available data (2019 to 2025), Entera Bio Ltd.'s Stockholders Equity has declined by 4.9%.
- Historical annual values: Fiscal year 2025: $13.10 million | Fiscal year 2024: $8.08 million | Fiscal year 2023: $10.39 million | Fiscal year 2022: $11.75 million | Fiscal year 2021: $22.57 million | Fiscal year 2020: $7.51 million | Fiscal year 2019: $13.77 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: